Business Context and Reporting Period
Phio Pharmaceuticals Corp. filed this Form 8-K on February 12, 2021, reporting the entry into a Material Definitive Agreement. The company is incorporated in Delaware and trades on The Nasdaq Capital Market under the symbol PHIO.
Key Financial Metrics
This filing details a capital raise rather than operational financial results. Key transaction metrics include:
- Shares Sold: 2,246,784 shares of Common Stock.
- Purchase Price: $3.42 per share.
- Net Proceeds: Approximately $6.9 million (after deducting fees and expenses).
- Placement Agent Fees: 7.5% cash fee, 1.0% management fee, and up to $85,000 for expenses.
- Warrants Issued: 168,509 Placement Agent Warrants (7.5% of shares sold) exercisable at $4.275 per share, expiring February 12, 2026.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the increase in equity capital and the issuance of new shares and warrants. The Offering closed on February 17, 2021. No comparative period financial data is provided in this specific filing.
Outlook, Risks, and Unusual Items
The transaction was conducted pursuant to a prospectus supplement and a shelf registration statement (Form S-3). The Placement Agent Warrants and underlying shares were sold without registration under the Securities Act of 1933, relying on exemptions for transactions not involving a public offering and sales to accredited investors. The filing incorporates the full text of the Securities Purchase Agreement and Placement Agent Warrants by reference.
Investor Verification Checklist
- Verify the final closing date of the Offering (stated as February 17, 2021).
- Confirm the exact net proceeds received after all fees and expenses.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants or restrictions.
- Assess the dilution impact of the 2,246,784 new shares and 168,509 warrants on existing shareholders.
- Check subsequent filings for the use of the $6.9 million in net proceeds.